Palisade Bio (PALI) Liabilities from Discontinued Operations (2020 - 2021)
Palisade Bio (PALI) posted quarterly Liabilities from Discontinued Operations of 219757.0 for Q1 2021, down 6.22% quarter-over-quarter from 234344.0 in Q4 2020.
Powered by 
Analysis
Palisade Bio (PALI) Liabilities from Discontinued Operations (2020 - 2021) Analysis & Trends
Palisade Bio (PALI) has reported Liabilities from Discontinued Operations for 2 consecutive years, with 219757.0 the latest figure, recorded in Q1 2021.
- In Q1 2021, Liabilities from Discontinued Operations changed N/A year-over-year to 219757.0; the TTM figure through Mar 2021 stood at 219757.0 (changed N/A YoY), while the FY2020 annual figure was 234344.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations retreated to 219757.0 in Q1 2021 per PALI's latest filing, from 234344.0 in the prior quarter.
- Across five years, Liabilities from Discontinued Operations topped out at 325812.0 in Q3 2020 and bottomed at 219757.0 in Q1 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Palisade Bio | 440.73 Mn | 315.53 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2021 | 219,757.00 |
| Dec 31, 2020 | 234,344.00 |
| Sep 30, 2020 | 325,812.00 |